REFERENCES
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., … Neoptolemos, J. P. (2016). Pancreatic cancer.Nature Reviews Disease Primers , 2 , 16022.https://doi.org/10.1038/nrdp.2016.22
Aier, I., Semwal, R., Sharma, A., & Varadwaj, P. K. (2019). A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. Cancer Epidemiology ,58 , 104-110.https://doi.org/10.1016/j.canep.2018.12.001
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA-A Cancer Journal for Clinicians , 68 , 394-424.https://doi.org/10.3322/caac.21492
Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA-A Cancer Journal for Clinicians , 70 , 7-30.https://doi.org/10.3322/caac.21590
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research , 74 , 2913-21.https://doi.org/10.1158/0008-5472.CAN-14-0155
Roth, M. T., Cardin, D. B., & Berlin, J. D. (2020). Recent advances in the treatment of pancreatic cancer. F1000Research , 9 , F1000 Faculty Rev-131.https://doi.org/10.12688/f1000 research.21981.1
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016). Pancreatic cancer. Lancet , 388 , 73-85.https://doi.org/10.1016/S0140-6736(16)00141-0
Binenbaum, Y., Na’ara, S., & Gil, Z. (2015). Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resistance Updates ,23 , 55-68.https://doi.org/10.1016/j.drup.2015.10.002
Dutta, P., Sabri, N., Li, J., & Li, W. X. (2015). Role of STAT3 in lung cancer. JAKSTAT , 3 , e999503.https://doi.org/10.1080/21623996.2014.999503
Banerjee, K., & Resat, H. (2016). Constitutive activation of STAT3 in breast cancer cells: A review. International Journal of Cancer ,138 , 2570-8.https://doi.org/10.1002/ijc.29923
Ouédraogo, Z. G., Biau, J., Kemeny, J. L., Morel, L., Verrelle, P., & Chautard, E. (2017). Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. Molecular Neurobiology , 54 , 5780-5797.https://doi.org/10.1007/s12035-016-0103-0
Liang, R., Chen, X., Chen, L., Wan, F., Chen, K., Sun, Y., & Zhu, X. (2020). STAT3 signaling in ovarian cancer: a potential therapeutic target. Journal of Cancer , 11 , 837-848.https://doi.org/10.7150/jca.35011
Carpenter, R. L., & Lo, H. W. (2014). STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel) , 6 , 897-925.https://doi.org/10.3390/cancers6020897
Kamran, M. Z., Patil, P., & Gude, R. P. (2013). Role of STAT3 in cancer metastasis and translational advances. Biomed Research International , 2013 , 421821.https://doi.org/10.1155/2013/421821
Wendt, M. K., Balanis, N., Carlin, C. R., & Schiemann, W. P. (2014). STAT3 and epithelial- mesenchymal transitions in carcinomas.JAKSTAT , 3 , e28975.https://doi.org/10.4161/jkst.28975
Gao, P., Niu, N., Wei, T., Tozawa, H., Chen, X., Zhang, C., … Liu, J. (2017). The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. Oncotarget ,8 , 69139-69161.https://doi.org/10.18632/oncotarget.19932
Demaria, M., Giorgi, C., Lebiedzinska, M., Esposito, G., D’Angeli, L., Bartoli, A., … Poli, V. (2010). A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) , 2 , 823-42.https://doi.org/10.18632/aging.100232
Galoczova, M., Coates, P., & Vojtesek, B. (2018). STAT3, stem cells, cancer stem cells and p63. Cellular & Molecular Biology Letters ,23 , 12.https://doi.org/10.1186/s11658-018-0078-0
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., … Yu, H. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine ,10 , 48-54.https://doi.org/10.1038/nm976
Fan, Y., Mao, R., & Yang, J. (2013). NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein & Cell ,4 , 176-85.https://doi.org/10.1007/s13238-013-2084-3
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014). Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nature Reviews Cancer , 14 , 736-746.https://doi.org/10.1038/nrc3818
Yu, H., Pardoll, D., & Jove, R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer ,9 , 798-809.https://doi.org/10.1038/nrc2734
Wang, Y., Shen, Y., Wang, S., Shen, Q., & Zhou, X. (2018). The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Letters , 415 , 117-128.https://doi.org/10.1016/j.canlet.2017.12.003
Yu, H., Kortylewski, M., & Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.Nature Reviews Immunology , 7 , 41-51.https://doi.org/10.1038/nri1995
Lee, H. J., Zhuang, G., Cao, Y., Du, P., Kim, H. J., & Settleman, J. (2014). Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell , 26 , 207-21.https://doi.org/10.1016/j.ccr.2014.05.019
Zhao, C., Li, H., Lin, H. J., Yang, S., Lin, J., & Liang, G. (2016). Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism.Trends in Pharmacological Sciences , 37 , 47-61.https://doi.org/10.1016/j.tips.2015.10.001
Johnson, D. E., O’Keefe, R. A., & Grandis, J. R. (2018). Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology , 15 , 234-248.https://doi.org/10.1038/nrclinonc.2018.8
Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P. (2016). Strategies and Approaches of Targeting STAT3 for Cancer Treatment.ACS Chemical Biology , 11 , 308-18.https://doi.org/10.1021/acschembio.5b00945
Scholz, A., Heinze, S., Detjen, K. M., Peters, M., Welzel, M., Hauff, P., … Rosewicz, S. (2003). Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology , 125 , 891-905.https://doi.org/10.1016/s0016-5085(03)01064-3
Fofaria, N. M., & Srivastava, S. K. (2015). STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. Carcinogenesis , 36 , 142-50.https://doi.org/10.1093/carcin/bgu233
He, W., Wu, J., Shi, J., Huo, Y. M., Dai, W., Geng, J., … Xue, J. (2018). IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer. Cancer Research , 78 , 3293-3305.https://doi.org/10.1158/0008-5472.CAN-17-3131
Wei, D., Le, X., Zheng, L., Wang, L., Frey, J. A., Gao, A. C., … Xie, K. (2003). Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene , 22 , 319-29.https://doi.org/10.1038/sj.onc.1206122
Li, N., Grivennikov, S. I., & Karin, M. (2011). The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment.Cancer Cell , 19 , 429-31.https://doi.org/10.1016/j.ccr.2011.03.018
D’Amico, S., Shi, J., Martin, B. L., Crawford. H. C., Petrenko, O., & Reich, N. C. (2018). STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. Genes & Development , 32 , 1175-1187.https://doi.org/10.1101/gad.311852.118
Tang, D., Liu, L. L., He, Q. R., Yan, W., Li, D., & Gao, J. M. (2018). Ansamycins with Antiproliferative and Antineuroinflammatory Activity from Moss-Soil-Derived Streptomyces cacaoi subsp. asoensis H2S5.Journal of Natural Products , 81 , 1984-1991.https://doi.org/10.1021/acs.jnatprod.8b00203
Liu, L. L., Chen, Z. F., Liu, Y., Tang, D., Gao, H. H., Zhang, Q., & Gao, J. M. (2020). Molecular networking-based for the target discovery of potent antiproliferative polycyclic macrolactam ansamycins from Streptomyces cacaoi subsp. Asoensis. Organic Chemistry Frontiers ,https://doi.org/10.1039/D0QO00557F
Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., … Ahluwalia, A. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. British Journal of Pharmacology , 175 , 407-411.https://doi.org/10.1111/bph.14112
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010). Animal research: Reporting in vivo experiments: The ARRIVE guidelines. British Journal of Pharmacology , 160 , 1577-1579.https://doi.org/10.1111/j.1476-5381.2010.00872.x
McGrath, J. C., & Lilley, E. (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. British Journal of Pharmacology , 172 , 3189-3193.https://doi.org/10.1111/bph.12955
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., … Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology ,175 , 987-993.https://doi.org/10.1111/bph.14153
Bharadwaj, U., Eckols, T. K., Xu, X., Kasembeli, M. M., Chen, Y., Adachi, M., … Tweardy, D. J. (2016). Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.Oncotarget , 7 , 26307-30.https://doi.org/10.18632/oncotarget.8368
Zhang, X., Yue, P., Page, B. D., Li, T., Zhao, W., Namanja, A. T., … Turkson, J. (2012). Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America , 109 , 9623-8.https://doi.org/10.1073/pnas.1121606109
Moore, A., & Donahue, T. (2019). Pancreatic Cancer. JAMA-Journal of the American Medical Association , 322 , 1426.https://doi.org/10.1001/jama.2019.14699
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018). Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology & Hepatology , 15 , 333-348.https://doi.org/10.1038/s41575-018-0005-x
Stan, S. D., Singh, S. V., & Brand, R. E. (2010). Chemoprevention strategies for pancreatic cancer. Nature Reviews Gastroenterology & Hepatology , 7 , 347-356.https://doi.org/10.1038/nrgastro.2010.61
Ying, J. E., Zhu, L. M., & Liu, B. X. (2012). Developments in metastatic pancreatic cancer: is gemcitabine still the standard?World Journal of Gastroenterology , 18 , 736-45.https://doi.org/10.3748/wjg.v18.i8.736
Akinleye, A., Iragavarapu, C., Furqan, M., Cang, S., & Liu, D. (2015). Novel agents for advanced pancreatic cancer. Oncotarget ,6 , 39521-39537.https://doi.org/10.18632/oncotarget.3999
Adamska, A., Elaskalani, O., Emmanouilidi, A., Kim, M., Razak, N. B. A., Metharom, P., & Falasca, M. (2018). Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Advances in Biological Regulation , 68 , 77-87.https://doi.org/10.1016/j.jbior.2017.11.007
Avalle, L., & Poli, V. (2018). Nucleus, Mitochondrion, or Reticulum? STAT3 à La Carte. International Journal of Molecular Sciences ,19 , 2820.https://doi.org/10.3390/ijms19092820
Swiatek-Machado, K., & Kaminska, B. (2020). STAT Signaling in Glioma Cells. Advances in Experimental Medicine and Biology ,1202 , 203-222.https://doi.org/10.1007/978-3-030-30651-9-10
Yu, H., & Jove, R. (2004). The STATs of cancer–new molecular targets come of age. Nature Reviews Cancer , 4 , 97-105.https://doi.org/10.1038/nrc1275
Huang, C., & Xie, K. (2012). Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine & Growth Factor Reviews , 23 , 25-35.https://doi.org/10.1016/j.cytogfr.2012.01.003
Venkatasubbarao, K., Peterson, L., Zhao, S., Hill, P., Cao, L., Zhou, Q., … Freeman, J. W. (2013). Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Molecular Cancer ,12 , 104.https://doi.org/10.1186/1476-4598-12-104
Debnath, B., Xu, S., & Neamati, N. (2012). Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein.Journal of Medicinal Chemistry , 55 , 6645-6668.https://doi.org/10.1021/jm300207s
Yang, L., Lin, S., Xu, L., Lin, J., Zhao, C., & Huang, X. (2018). Novel activators and small-molecule inhibitors of STAT3 in cancer.Cytokine & Growth Factor Reviews , 49 , 10-22.https://doi.org/10.1016/j.cytogfr.2019.10.005
Beebe, J. D., Liu, J. Y., & Zhang, J. T. (2018). Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharmacology & Therapeutics , 191 , 74-91.https://doi.org/10.1016/j.pharmthera.2018.06.006